Alkermes Plc at Cowen Health Care Conference Transcript
Good morning, let's get underway. My name is Chris Shibutani, I'm a member of the Cowen biotech equity research team. Very pleased, as always, to have Alkermes join us. I think when we think about the phrase unmet needs, tends to be a little bit trite and overused, and we think about, sort of, the scope and the complexity of some of the problems that are truly societal health and global unmet needs, it's rare companies that, I think, think mind capabilities and frankly, some courage and grit to tackle some of these problems. It takes a lot of effort, navigating complex paths and the willingness to be resilient. And in particular for investors now, I think that there's an interesting opportunity to recognize what the durability of some of these needs are, what the franchise value is of a company like Alkermes as they take on some of these challenges when we think about addiction, mental illness and even oncology in terms of expanding their capabilities.
Here to provide us with an update, Richard Pops, CEO
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |